Your browser doesn't support javascript.
loading
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
Huiberts, Anne J; Hoeve, Christina E; de Gier, Brechje; Cremer, Jeroen; van der Veer, Bas; de Melker, Hester E; van de Wijgert, Janneke Hhm; van den Hof, Susan; Eggink, Dirk; Knol, Mirjam J.
Afiliación
  • Huiberts AJ; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • Hoeve CE; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • de Gier B; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • Cremer J; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • van der Veer B; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • de Melker HE; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • van de Wijgert JH; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.
  • van den Hof S; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • Eggink D; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • Knol MJ; These authors contributed equally to this article and share last authorship.
Euro Surveill ; 29(10)2024 Mar.
Article en En | MEDLINE | ID: mdl-38456217
ABSTRACT
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI 23-55) in 18-59-year-olds and 50% (95% CI 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI0.8-2.6).
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Límite: Adult / Humans País/Región como asunto: Europa Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Límite: Adult / Humans País/Región como asunto: Europa Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos